Adamas Pharmaceuticals, Inc. (ADMS) Reaches $32.32 After 9.00% Up Move; 2 Analysts Covering ARC Document Solutions, Inc. (ARC)

May 17, 2018 - By Vivian Park

ARC Document Solutions, Inc. (NYSE:ARC) Logo

Among 5 analysts covering ARC Document Solutions (NYSE:ARC), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. ARC Document Solutions had 10 analyst reports since August 7, 2015 according to SRatingsIntel. Zacks downgraded the stock to “Sell” rating in Monday, September 7 report. B. Riley & Co initiated ARC Document Solutions, Inc. (NYSE:ARC) on Friday, January 8 with “Buy” rating. The firm has “Hold” rating given on Thursday, November 2 by FBR Capital. As per Tuesday, October 20, the company rating was initiated by Sidoti. The rating was maintained by B. Riley & Co on Monday, March 20 with “Buy”. The rating was upgraded by Zacks on Monday, August 31 to “Sell”. The firm earned “Hold” rating on Friday, August 7 by TheStreet. William Blair downgraded the shares of ARC in report on Thursday, November 5 to “Market Perform” rating. The firm has “Hold” rating by Zacks given on Tuesday, August 25. See ARC Document Solutions, Inc. (NYSE:ARC) latest ratings:




The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is a huge mover today! The stock increased 2.31% or $0.73 during the last trading session, reaching $32.32. About 377,851 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 35.83% since May 17, 2017 and is uptrending. It has outperformed by 24.28% the S&P500.The move comes after 5 months positive chart setup for the $872.07M company. It was reported on May, 17 by Barchart.com. We have $35.23 PT which if reached, will make NASDAQ:ADMS worth $78.49 million more.

Another recent and important ARC Document Solutions, Inc. (NYSE:ARC) news was published by Seekingalpha.com which published an article titled: “ARC Document Solutions’ (ARC) CEO Suri Suriyakumar on Q1 2018 Results – Earnings Call Transcript” on May 01, 2018.

Investors sentiment increased to 1.29 in 2017 Q4. Its up 0.15, from 1.14 in 2017Q3. It improved, as 11 investors sold ARC Document Solutions, Inc. shares while 27 reduced holdings. 17 funds opened positions while 32 raised stakes. 30.52 million shares or 3.97% less from 31.78 million shares in 2017Q3 were reported. Blair William Il has 0% invested in ARC Document Solutions, Inc. (NYSE:ARC). Spark Inv Mngmt Ltd stated it has 0.02% of its portfolio in ARC Document Solutions, Inc. (NYSE:ARC). 33,983 are held by Clarivest Asset Mngmt Limited Liability Company. New York State Common Retirement Fund holds 0% of its portfolio in ARC Document Solutions, Inc. (NYSE:ARC) for 37,200 shares. Tower Research Limited Liability Corp (Trc) holds 0% of its portfolio in ARC Document Solutions, Inc. (NYSE:ARC) for 2,734 shares. Panagora Asset Mngmt reported 635,612 shares. Vanguard Group Incorporated, a Pennsylvania-based fund reported 1.51M shares. State Board Of Administration Of Florida Retirement Systems holds 0% or 37,690 shares in its portfolio. Renaissance Techs Ltd Company holds 2.86M shares. California Employees Retirement Systems reported 0% stake. Bridgeway Mngmt invested in 0.01% or 519,500 shares. Moreover, Cornerstone Capital Mngmt Ltd Liability Corporation has 0% invested in ARC Document Solutions, Inc. (NYSE:ARC). Northern Tru Corporation holds 0% in ARC Document Solutions, Inc. (NYSE:ARC) or 450,455 shares. Rhumbline Advisers owns 42,646 shares. Moreover, Deutsche Bank & Trust Ag has 0% invested in ARC Document Solutions, Inc. (NYSE:ARC) for 89,278 shares.

Since December 29, 2017, it had 3 insider buys, and 1 sale for $32,429 activity. Grimes Dennis Jeffery had bought 1,383 shares worth $3,001 on Friday, December 29. Shares for $25,725 were sold by Roy Rahul K. PEREZ DE LA MESA MANUEL J also bought $47,000 worth of ARC Document Solutions, Inc. (NYSE:ARC) shares.

The stock decreased 2.76% or $0.06 during the last trading session, reaching $2.11. About 75,281 shares traded. ARC Document Solutions, Inc. (NYSE:ARC) has declined 42.11% since May 17, 2017 and is downtrending. It has underperformed by 53.66% the S&P500.

ARC Document Solutions, Inc., a reprographics company, provides document solutions worldwide. The company has market cap of $95.50 million. It offers managed print services, an onsite service that places, manages, and optimizes print and imaging equipment in customers' offices, job sites, and other facilities; and operates 177 offsite service centers that offer managed print service clients with the flexibility and overflow capacity during peak workloads. It currently has negative earnings. The firm also provides archive and information management services; and specialized color printing comprising color printing, finishing and assembly of graphic materials for regional and national retailers, franchises, marketing departments, theme parks, and cultural institutions.

Among 13 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Adamas Pharmaceuticals had 36 analyst reports since August 7, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 9 report. Mizuho maintained the shares of ADMS in report on Tuesday, February 20 with “Buy” rating. The firm has “Buy” rating given on Friday, August 25 by Mizuho. The firm earned “Market Outperform” rating on Friday, August 25 by JMP Securities. Noble Financial initiated Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Friday, June 17. Noble Financial has “Buy” rating and $25 target. The firm has “Neutral” rating given on Thursday, April 28 by Mizuho. Credit Suisse maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Thursday, December 24 with “Outperform” rating. The firm has “Buy” rating by Piper Jaffray given on Thursday, February 22. The stock has “Buy” rating by Zacks on Friday, August 7. The firm has “Neutral” rating by Mizuho given on Tuesday, January 19.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $872.07 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.

ARC Document Solutions, Inc. (NYSE:ARC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts